Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) FCF Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed FCF Margin for 16 consecutive years, with 171.61% as the latest value for Q4 2025.

  • For Q4 2025, FCF Margin fell 12194.0% year-over-year to 171.61%; the TTM value through Dec 2025 reached 246.03%, down 12725.0%, while the annual FY2025 figure was 246.03%, 12941.0% down from the prior year.
  • FCF Margin hit 171.61% in Q4 2025 for Sangamo Therapeutics, up from 4916.01% in the prior quarter.
  • Across five years, FCF Margin topped out at 23.89% in Q3 2024 and bottomed at 10212.68% in Q1 2024.
  • Average FCF Margin over 5 years is 1535.17%, with a median of 236.96% recorded in 2022.
  • Year-over-year, FCF Margin tumbled -1016743bps in 2024 and then skyrocketed 980282bps in 2025.
  • Sangamo Therapeutics' FCF Margin stood at 271.59% in 2021, then rose by 13bps to 236.96% in 2022, then plummeted by -1000bps to 2605.73% in 2023, then surged by 98bps to 49.68% in 2024, then tumbled by -245bps to 171.61% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 171.61%, 4916.01%, and 98.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.